Opus Genetics (IRD) Expected to Announce Quarterly Earnings on Thursday

Opus Genetics (NASDAQ:IRD) will likely be posting its quarterly earnings results on Thursday, March 6th. Analysts expect Opus Genetics to post earnings of ($0.02) per share and revenue of $11.10 million for the quarter.

Opus Genetics Stock Performance

NASDAQ IRD opened at $1.07 on Thursday. Opus Genetics has a twelve month low of $0.81 and a twelve month high of $2.65. The firm has a market cap of $33.78 million, a P/E ratio of -0.98 and a beta of 0.16. The firm’s fifty day moving average price is $1.16.

Insider Buying and Selling

In related news, CEO George Magrath bought 100,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was acquired at an average cost of $0.98 per share, with a total value of $98,000.00. Following the transaction, the chief executive officer now directly owns 599,150 shares in the company, valued at approximately $587,167. This trade represents a 20.03 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Opus Genetics in a report on Wednesday, February 19th.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.